Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse.

Slides:

Advertisements

Similar presentations

Peter J Voshol, PhD Director of Disease Model Core Senior Research Associate: Integrative Physiology Disease Model Core Metabolic Phenotyping: which parameters.

Advertisements

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2007 年１月 11 日 8:20-8:50 B 棟８階カンファレンス室.

Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:

Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.

Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

Figure 1. A schematic representation of the stress system

Circadian Rhythms of Women with Fibromyalgia1

Figure 1. Schematic representation of TSHR

Fig. 1. Time line for investigations

Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.

From: Pharmacologic Therapy for Type 2 Diabetes Mellitus

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.

Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs of the FTO gene. The P values are for the additive model.

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

Fig. 1. Study enrollment and disposition of participants

Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.

Glucose tolerance testing. A

Fig. 1. Left, Total ghrelin; right, octanoylated ghrelin

Nat. Rev. Endocrinol. doi: /nrendo

Fig. 4. Single total plasma 8-isoprostane levels in both controls and type 2 diabetic patients. Diabetes Induces p66shc Gene Expression in Human Peripheral.

Figure 1. Circadian pattern of gastric pH in healthy control subjects documented before (P1) Ramadan, on the 10th day (P2) and on the 24th day (P3) of.

Figure 1. Consort flow diagram.

Fig. 1. Flow of subjects through different phases of the study.

Fig. 1. Active GLP-1 and total PYY in response to a liquid test meal

From: Low Vitamin D Status despite Abundant Sun Exposure

HT (n = 45), healthy control subjects (HC) (n = 22), DTC-I, recurrent or persistent DTC (n = 27), DTC-II, disease free DTC (n = 34). Tg clusters are defined.

Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

From: Effect of a Low-Carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes Ann Intern Med.

Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.

Figure 1. Summary of PTH secretion from human parathyroid cells after caffeine treatment at concentrations of 0, 1, 10, and 50 μm at extracellular calcium.

Figure 1. TAK-448 structure (A) and effect on the hypothalamic-pituitary-gonadal axis (B). At the normal physiological state, GnRH pulses in the hypothalamus.

Predicted values and SEs were based on linear mixed models

Figure 1. Melatonin levels in CSF of control subjects (n = 82) and AD patients (n = 85). *, P< Decreased Melatonin Levels in Postmortem Cerebrospinal.

Fig. 3. Mean body weight of women randomized to low-carbohydrate and low-fat diets over the course of the 4-month trial. The first time point (wk 1) represents.

Figure 1. Height distribution for adults with AIS.

Figure 1. Serum concentrations of IGF-I (A), IGF-II (B), IGFBP-3 (C), and ALS (D) throughout life in GHD (closed circles) and healthy control (open circles)

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Figure 4. Inhibition of LPS-induced IL-1β and TNFα, but not IL-6, after exercise. Depicted are LPS-induced IL-1β (upper panel), IL-6 (middle panel), and.

Fig. 4. Relationships of changes in CRP or SAA to changes in body weight and insulin resistance. For each comparison the regression line is shown (solid.

Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.

Fig. 1. Serum levels of IGF-I vs

Volume 15, Issue 7, Pages (May 2016)

Nat. Rev. Nephrol. doi: /nrneph

Volume 126, Issue 3, Pages (March 2004)

Volume 146, Issue 3, Pages (March 2014)

Volume 132, Issue 1, Pages (January 2007)

Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

Mikko Syvänne, MD, Marja-Riitta Taskinen, MD The Lancet

James F. List, Jean M. Whaley Kidney International

Volume 133, Issue 2, Pages (August 2007)

Volume 138, Issue 3, Pages e3 (March 2010)

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Volume 368, Issue 9541, Pages (September 2006)

Volume 135, Issue 1, Pages (July 2008)

Figure 1. Randomization and dropouts.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Relationships between NEFA release from subcutaneous abdominal adipose tissue and fat mass (A) and fasting insulin (B) in different groups of subjects.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Effects of Rosi treatment on ASKO mice.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Presentation transcript:

Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse cross-sectional view (left upper), sagittal view (right upper), and coronal view (left lower) before and after pioglitazone treatment. The transverse cross-sectional view at the L4–5 vertebral level was used in the measurement of sc and visceral fat areas. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6):2784-2791. doi:10.1210/jcem.87.6.8567 J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

Figure 2. Index of hepatic insulin resistance (basal EGP × basal IRI) before and after 16 wk of pioglitazone treatment, where EGP is the endogenous glucose production (milligrams per kilogram FFM per minute) during the basal period, and IRI is the immunoreactive insulin concentration (microunits per milliliter). Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6):2784-2791. doi:10.1210/jcem.87.6.8567 J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

Figure 3. Total body glucose MCR (milliliters per kilogram FFM per minute) during the first and second steps of the insulin clamp performed before and after 16 wk of pioglitazone treatment. *, P < 0.05; **, P < 0.01 (before vs. after pioglitazone). From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6):2784-2791. doi:10.1210/jcem.87.6.8567 J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

Figure 4. Association between visceral fat area (left)/sc fat area (right) at the L4–5 vertebral level and hepatic insulin resistance (basal EGP × basal IRI) before and after 16 wk of pioglitazone treatment combined. Open symbols, Before pioglitazone; closed symbols, after pioglitazone. Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6):2784-2791. doi:10.1210/jcem.87.6.8567 J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

Figure 5. Association between visceral fat area (left)/sc fat area (right) at L4–5 vertebral level and total body glucose MCR during the first and second steps of the insulin clamp performed before and after 16 wk of pioglitazone treatment. Open symbols, Before pioglitazone; closed symbols, after pioglitazone. Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6):2784-2791. doi:10.1210/jcem.87.6.8567 J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

Figure 6. Relationship between hepatic insulin resistance (basal EGP × basal insulin concentration) and the fasting plasma FFA concentration in diabetic patients before (open symbols) and after (closed symbols) pioglitazone treatment. Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6):2784-2791. doi:10.1210/jcem.87.6.8567 J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society